Biobank for pancreatic adenocarcinoma research
Anatomical-Clinical Base of Adenocarcinoma Pancreatic
This study is collecting samples and information from people with pancreatic cancer to help find better ways to diagnose and treat the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years to 120 Years |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 8 sites (Béthune and 7 other locations) |
| Trial ID | NCT06128343 on ClinicalTrials.gov |
What this trial studies
BACAP-2 is a prospective biobank focused on collecting clinical data and biological samples from patients with pancreatic adenocarcinoma. The study aims to enhance the existing BACAP collection to support future research projects aimed at improving diagnosis and treatment of pancreatic cancer. It addresses the challenges of timely diagnosis and the need for new therapeutic targets by analyzing fresh tumor tissue and somatic genetic data. The ultimate goal is to develop new diagnostic tools and understand tumor development and chemotherapy responses.
Who should consider this trial
Good fit: Ideal candidates include patients with a histologically or cytologically proven diagnosis of pancreatic adenocarcinoma or those with pancreatic mass syndrome undergoing specific imaging studies.
Not a fit: Patients with pancreatic tumors that are not adenocarcinomas or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and treatment options for patients with pancreatic adenocarcinoma.
How similar studies have performed: Other studies focusing on biobanks for cancer research have shown success in advancing understanding and treatment options, making this approach promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with pancreatic mass syndrome explored by ultrasound endoscopy with cytopuncture or * Patient with pancreatic mass syndrome explored by an abdominal scanner with and without injection of product contrast and/or puncture of the mass or secondary lesions by radiological route or * Patient with pancreatic adenocarcinoma proven histologically and/or cytologically Exclusion Criteria: * Patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma * Pregnant or breastfeeding patient
Where this trial is running
Béthune and 7 other locations
- Béthune hospital center — Béthune, France (Not_yet_recruiting)
- Haut-Lévêque Hospital — Bordeaux, France (Not_yet_recruiting)
- Huriez Hospital — Lille, France (Not_yet_recruiting)
- Jean Mermoz private hosptila — Lyon, France (Not_yet_recruiting)
- Saint Eloi Hospital — Montpellier, France (Not_yet_recruiting)
- Regional Cancer Center From Montpellier — Montpellier, France (Not_yet_recruiting)
- PAU hospital — Pau, France (Not_yet_recruiting)
- Rangueil hospital — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Barbara BOURNET, MD, PhD — University Hospital, Toulouse
- Study coordinator: Barbara BOURNET, MD, PhD
- Email: bournet.b@chu-toulouse.fr
- Phone: (0)5 61 32 32 35
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.